Antimicrobial resistance and biofilm formation among clinical Pseudomonas aeruginosa isolates from a tertiary care hospital in Nepal
This study conducted at a tertiary care hospital in Nepal reveals a high prevalence of biofilm formation (80.33%) and significant antimicrobial resistance, including ESBL, carbapenemase, and MBL production, among clinical *Pseudomonas aeruginosa* isolates, highlighting the urgent need for strengthened antimicrobial stewardship and infection control measures.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the hidden corners of hospitals, from the damp surfaces of sinks to the inside of breathing tubes, a single type of bacteria often waits. It is a tough, opportunistic germ that rarely makes healthy people sick but thrives when the body is weak. This bacterium, known as Pseudomonas aeruginosa, is a master of survival. It has two main tricks that make it dangerous in a medical setting. First, it can build a protective shield around itself, a slimy layer called a biofilm that acts like a fortress, keeping antibiotics out. Second, it can produce special enzymes that act like molecular scissors, cutting up and destroying many of the drugs doctors use to kill it. When these two traits combine, infections become incredibly difficult to treat, leaving patients with few options.
A team of researchers at a major hospital in Dharan, Nepal, recently set out to understand how common these traits are in their local patient population. They looked at nearly 3,600 samples taken from people who were sick enough to be tested for bacterial infections. From these samples, they found 178 cases where Pseudomonas aeruginosa was the culprit. The researchers wanted to know not just how often this germ appeared, but also how well it could resist modern medicines and how often it built those protective biofilm shields. They examined the bacteria's ability to produce the drug-cutting enzymes and tested whether the bacteria that formed biofilms were also the ones most likely to survive treatment.
The study revealed that this bacterium was present in about five out of every hundred positive cultures, a rate similar to what other hospitals in the region have seen. It was found most often in patients who were already staying in the hospital, particularly in samples taken from pus, wound swabs, and urine. When the researchers tested the bacteria against a list of common antibiotics, they found a mixed picture. The germs were still quite sensitive to a few powerful drugs, with about three-quarters of them being killed by imipenem and meropenem. However, resistance was high against other common treatments, with the bacteria showing the least ability to be stopped by a combination drug called piperacillin-tazobactam.
Perhaps more concerning was the discovery of the bacteria's hidden defenses. The researchers found that nearly a quarter of the bacteria were producing enzymes that cut up extended-spectrum cephalosporins, a major class of antibiotics. Even more troubling, about 29 percent of the isolates were producing enzymes capable of destroying carbapenems, which are often considered the last line of defense against serious infections. Within that group, nearly 19 percent were making a specific type of enzyme called a metallo-beta-lactamase, which is particularly effective at neutralizing these last-resort drugs.
The study also shed light on the bacteria's ability to form biofilms. Using two different testing methods, the researchers found that over 80 percent of the bacteria were capable of building these protective communities. This was not just a random occurrence; the data showed a clear link between the bacteria that formed biofilms and their resistance to antibiotics. The bacteria that built these shields were significantly more likely to survive treatment with drugs like gentamicin, tobramycin, amikacin, ciprofloxacin, and meropenem. In fact, the presence of a biofilm made the bacteria much harder to kill with these specific medicines compared to those that did not form a shield.
The researchers concluded that the situation in this hospital is serious. The combination of high rates of drug resistance and the widespread ability to form biofilms means that treating infections caused by this bacterium is becoming increasingly difficult. They noted that while their study was limited to one hospital and relied on visual tests rather than genetic sequencing, the results point to a growing threat. The authors suggest that strict control of infections within the hospital and careful management of how antibiotics are prescribed are essential to slow down the spread of these resistant strains. Without these measures, the options for treating patients with this tough germ will continue to shrink.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.